FOOD AN	HEALTH AND HUM D DRUG ADMINISTRAT	TION	
DISTRICT ADDRESS AND PHONE NUMBER		DATE(S) OF INSPECTION	
One Montvale Avenue		12/9/2015-12/11/2015 FEI NUMBER	
Stoneham, MA 02180		3004123934	
(781)587-7500 Fax: (781)587-7556			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED		1	
Margaret M. Hudlin , Chief Medical Of	ficer		
FIRM NAME	STREET ADDRESS		
Umass Memorial Medical Center	55 Lake Avenue North		
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED		
Worcester, MA 01655-0002	Hospital/User Facility		
This document lists observations made by the FDA representations, and do not represent a final Agency determination observation, or have implemented, or plan to implement, correspond to with the FDA representative(s) during the inspection or questions, please contact FDA at the phone number and address	on regarding your co ective action in respo r submit this informa	impliance. If you have an objection regarding an onse to an observation, you may discuss the objection or	

The observations noted in this Form FDA-483 are not an exhaustive listing of objectionable conditions. Under the law, your firm is responsible for conducting internal self-audits to identify and correct any and all violations of the quality system requirements.

#### DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:

#### **OBSERVATION 1**

The written MDR Procedure does not include an internal system which provides for the timely and effective identification and communication and evaluation of events that may be subject to medical device reporting requirements.

# Specifically,

- A) Your hospital/user facility did not submit a Medical Device Report, within 10 working days of becoming aware of the b(3) incident (Incident number b(3)) of patients that were infected with the same strain of b(3) and b(3) and found that b(3) were used on the patients. Of these, 3 patients died (2 of the 3 patients had complicated illnesses).
- B) Your hospital/user facility has not submitted a Medical Device Report within 10 working days of becoming aware of the b(3) incident (Incident Report Number b(3)) of an b(3) sustaining b(3).
- C) Timeframes for submitting MDR reports to FDA and manufacturers through Medsun are not defined in the Risk Management Procedure.

#### **OBSERVATION 2**

MDR event files have not been established and maintained.

	EMPLOYEE(S) SIGNATURE		DATE ISSUED
SEE REVERSE	Jeffrey J Thibodeau, Investigator	12/11/2015	12/11/2015
OF THIS PAGE	Sherry K Markwell, Investigator	X Jeffrey J Thibodeau	
		Jeffrey J Th bodeau Investigator Signed by: Jeffrey J. Thibodeau -S	

FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 1 OF 3 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION				
One Montvale Avenue	12/9/2015-12/11/2015				
Stoneham, MA 02180 (781)587-7500 Fax:(781)587-7556	3004123934				
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED					
Margaret M. Hudlin , Chief Medical Officer					
FIRM NAME	STREET ADDRESS				
Umass Memorial Medical Center	55 Lake Avenue North				
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED				
Worcester, MA 01655-0002	Hospital/User Facility				

## Specifically,

Although your hospital/user facility participates in MedSun to submit Medical Device Reports to FDA and Manufacturers, your hospital/user facility has not established and maintained documentation used to determine if a device-related death, serious injury, or malfunction was or was not reportable. For example:

- 1. The hospital's incident reporting system is not linked to MDR files and patient records for compilation of data.
- 2. The decision making process for MDR reportability is not documented.
- 3. There is no corresponding business file to allow staff to easily identify and access corresponding information to MDRs.

#### **OBSERVATION 3**

The user facility did not submit FDA Form 3500A or electronic equivalent to the known device manufacturer within 10 working days of becoming aware of information that reasonably suggests that a device has or may have caused or contributed to a serious injury to a patient of the facility.

## Specifically,

An event of life threatening serious injury occurred b(3) b(6) for rupture of the b(3) on the under Report b(3) and was submitted through MedSun on b(3) , outside of the 10 working day requirement.

## **Annotations to Observations**

Observation 1: Under consideration
Observation 2: Under consideration
Under consideration
Under consideration

Sherry K Markwell
Sherry K Markwell
Investigator
Singed by: Sherry K, Markwell -5

	EMPLOYEE(S) SIGNATURE		DATE ISSUED
The state of the s	Jeffrey J Thibodeau, Investigator Sherry K Markwell, Investigator	X Jeffrey J Thibodeau	12/11/2015
		Jeffrey J Th bodeau Investigator Signed by: Jeffrey J. Thibodeau -S	

FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 2 OF 3 PAGES

The observations of objectionable conditions and practices listed on the front of this form are reported:

- 1. Pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, or
- 2. To assist firms inspected in complying with the Acts and regulations enforced by the Food and Drug Administration.

Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC 374(b)) provides:

"Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary."